The FDA approved maribavir (Livtencity, Takeda) as the first drug for treating patients 12 years of age and older and weighing at least 35 kilograms with post-transplant cytomegalovirus (CMV) infection/disease that does not respond to available antiviral treatment for CMV, whether or not they have genes for resistance to other therapies.
Maribavir works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.